CD146-mediated acquisition of stemness phenotype enhances tumour invasion and metastasis after EGFR-TKI resistance in lung cancer
Author:
Affiliation:
1. Department of Respiratory Medicine; Henan Provincial People’s Hospital; Zhengzhou Henan China
2. Clinical Research Center; Henan Provincial People’s Hospital; Zhengzhou Henan China
Funder
Science and Technology Agency of Henan province in China
National Natural Science Foundation of China
Publisher
Wiley
Subject
Genetics (clinical),Pulmonary and Respiratory Medicine,Immunology and Allergy
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/crj.12976/fullpdf
Reference45 articles.
1. Cancer statistics, 2017;Siegel;CA Cancer J Clin,2017
2. Lung cancer-time to move on from chemotherapy;Carney;N Engl J Med,2002
3. Phase II trial of a trimodality regimen for stage III non-small-cell lung cancer using chemotherapy as induction treatment with concurrent hyperfractionated chemoradiation with carboplatin and paclitaxel followed by subsequent resection: a single-center study;Friedel;J Clin Oncol,2010
4. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib;Lynch;N. Engl. J. Med,2004
5. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy;Paez;Science,2004
Cited by 19 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. CD146, a therapeutic target involved in cell plasticity;Science China Life Sciences;2024-04-09
2. CD146 Promotes EMT-Mediated Migration and Invasion of NSCLC via PI3K/Akt Signaling Pathway;Frontiers in Bioscience-Landmark;2024-04-08
3. CD146 promotes malignant progression of breast phyllodes tumor through suppressing DCBLD2 degradation and activating the AKT pathway;Cancer Communications;2023-10-19
4. Tumor Microenvironmental Cytokines Drive NSCLC Cell Aggressiveness and Drug-Resistance via YAP-Mediated Autophagy;Cells;2023-03-30
5. CD146‐targeted nuclear medicine imaging in cancer: State of the art;VIEW;2023-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3